Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects

Xuanyou Jin, Eunwoo Kim, Ki Young Huh, Inyoung Hwang, Joo-Youn Cho, Kyung-Sang Yu, SeungHwan Lee, Xuanyou Jin, Eunwoo Kim, Ki Young Huh, Inyoung Hwang, Joo-Youn Cho, Kyung-Sang Yu, SeungHwan Lee

Abstract

A fixed-dose combination (FDC) of gemigliptin/metformin can improve the medication adherence in patients with type 2 diabetes mellitus (T2DM). In this study, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of gemigliptin and metformin were compared between FDC and the corresponding loose combination under fasted and fed states. A two-part, randomized, open label, single-dose, two-way crossover study was conducted in healthy male subjects. Under fasted (part 1) or fed (part 2) state, 2 FDC tablets of gemigliptin/metformin sustained release (SR) 25/500 mg or loose combination with one tablet of gemigliptin 50 mg and two tablets of metformin extended release (XR) 500 mg were orally administered in each period with a 7-day washout. Serial blood samples were collected up to 48 hours to determine the drug concentration and the dipeptidyl peptidase 4 (DPP-4) activity. The concentration-time profiles of gemigliptin and metformin were similar between FDC and loose combination in both the fasted and fed states. Geometric mean ratios and 90% confidence intervals of FDC to loose combination for area under the concentration-time curve and maximum plasma concentration of gemigliptin and metformin were within the bioequivalence range (0.8-1.25) in both states. DPP-4 activity-time profiles of FDC were comparable to that of the loose combination, showing similar area under the DPP-4 inhibition-time curve and maximum DPP-4 inhibition between FDC and loose combination, regardless of the fasted or fed state. In conclusion, the PK/PD characteristics of gemigliptin and metformin were similar in FDC tablets and loose combination both in fasted and fed states.

Trial registration: ClinicalTrials.gov Identifier: NCT03355014.

Keywords: Fixed-dose combination; Gemigliptin; Metformin.

Conflict of interest statement

Conflict of interest: - Authors: Nothing to declare - Reviewers: Nothing to declare - Editors: Nothing to declare

Copyright © 2020 Translational and Clinical Pharmacology.

Figures

Figure 1. Mean plasma concentration-time profiles of…
Figure 1. Mean plasma concentration-time profiles of (A) gemigliptin, (B) LC15-0636, and (C) metformin after a single administration of 2 fixed-dose combination of gemigliptin/metformin SR 25/500 mg or loose combination with gemigliptin 50 mg and metformin XR 1,000 mg in fasted state. The error bars denote the standard deviations.
SR, sustained release; XR, extended release.
Figure 2. Mean plasma concentration-time profiles of…
Figure 2. Mean plasma concentration-time profiles of (A) gemigliptin, (B) LC15-0636, and (C) metformin after a single administration of 2 fixed-dose combination of gemigliptin/metformin SR 25/500 mg or loose combination with gemigliptin 50 mg and metformin XR 1,000 mg in fed state. The error bars denote the standard deviations.
SR, sustained release; XR, extended release.
Figure 3. Mean plasma concentration-time profiles for…
Figure 3. Mean plasma concentration-time profiles for DPP-4 activity after a single administration of 2 fixed-dose combination of gemigliptin/metformin SR 25/500 mg and corresponding loose combination in (A) fasted and (B) fed states. The error bars denote the standard deviations.
DDP-4, dipeptidyl peptidase 4; SR, sustained release; mOD, milli optical density.

References

    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62–S69.
    1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–372.
    1. American Diabetes Association 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2019 . Diabetes Care. 2019;42:S90–S102.
    1. Penfornis A, Bourdel-Marchasson I, Quere S, Dejager S. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. Diabetes Metab. 2012;38:550–557.
    1. Ahrén B. DPP-4 inhibition and the path to clinical proof. Front Endocrinol (Lausanne) 2019;10:376.
    1. Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, Pitale SU, et al. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:410–416.
    1. Kim SH, Lee SH, Yim HJ. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch Pharm Res. 2013;36:1185–1188.
    1. Lim KS, Cho JY, Kim BH, Kim JR, Kim HS, Kim DK, et al. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br J Clin Pharmacol. 2009;68:883–890.
    1. Shon JH, Kim N, Park SJ, Oh MK, Kim EY, Lee SH, et al. Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444) Diabetes Obes Metab. 2014;16:1028–1031.
    1. U.S. Food and Drug Administration. Glucophage (metformin hydrochloride tablets) Label Information. Silver Spring (MD): U.S. Food and Drug Administration; 2010.
    1. Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu. 2007:13–20.
    1. Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15:291–300.
    1. Shin D, Cho YM, Lee S, Lim KS, Kim JA, Ahn JY, et al. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clin Drug Investig. 2014;34:383–393.
    1. Lim S, Han KA, Yu J, Chamnan P, Kim ES, Yoon KH, et al. INICOM Study Group Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) Diabetes Obes Metab. 2017;19:87–97.
    1. Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, et al. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects. Drug Des Devel Ther. 2015;9:729–736.
    1. Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J. 2008;10:401–409.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅